[go: up one dir, main page]

NO20033247D0 - Bifunksjonelle fusjonsproteiner med glukocerebrosidaseaktivitet - Google Patents

Bifunksjonelle fusjonsproteiner med glukocerebrosidaseaktivitet

Info

Publication number
NO20033247D0
NO20033247D0 NO20033247A NO20033247A NO20033247D0 NO 20033247 D0 NO20033247 D0 NO 20033247D0 NO 20033247 A NO20033247 A NO 20033247A NO 20033247 A NO20033247 A NO 20033247A NO 20033247 D0 NO20033247 D0 NO 20033247D0
Authority
NO
Norway
Prior art keywords
fusion proteins
bifunctional fusion
glucocerebrosidase activity
glucocerebrosidase
activity
Prior art date
Application number
NO20033247A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033247L (no
Inventor
Silke Schumacher
Stephen D Gillies
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20033247L publication Critical patent/NO20033247L/no
Publication of NO20033247D0 publication Critical patent/NO20033247D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20033247A 2001-01-18 2003-07-17 Bifunksjonelle fusjonsproteiner med glukocerebrosidaseaktivitet NO20033247D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101056 2001-01-18
PCT/EP2001/015328 WO2002057435A2 (fr) 2001-01-18 2001-12-27 Proteines de fusion bifonctionnelles avec activite de la glucocerebrosidase

Publications (2)

Publication Number Publication Date
NO20033247L NO20033247L (no) 2003-07-17
NO20033247D0 true NO20033247D0 (no) 2003-07-17

Family

ID=8176235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033247A NO20033247D0 (no) 2001-01-18 2003-07-17 Bifunksjonelle fusjonsproteiner med glukocerebrosidaseaktivitet

Country Status (13)

Country Link
US (1) US20040043457A1 (fr)
EP (1) EP1392826A2 (fr)
JP (1) JP2004525621A (fr)
KR (1) KR20030067755A (fr)
CN (1) CN1630720A (fr)
BR (1) BR0116803A (fr)
CA (1) CA2435037A1 (fr)
HU (1) HUP0401300A3 (fr)
MX (1) MXPA03006294A (fr)
NO (1) NO20033247D0 (fr)
PL (1) PL362394A1 (fr)
WO (1) WO2002057435A2 (fr)
ZA (1) ZA200306333B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP1071468B1 (fr) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Co-administration d'un inhibiteur de l'angiogenese pour renforcer la reponse immunitaire a mediation de proteine de fusion d'une cytokine d'anticorps
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (de) * 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
PT1294401E (pt) * 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
EP2354791A1 (fr) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines a selectivite modulee
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
ES2438098T3 (es) 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
WO2005070967A2 (fr) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anticorps anticancereux a fixation complementaire reduite
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1920061A4 (fr) 2005-07-27 2009-05-13 Wang Qinghua CONSTRUCTIONS DE FUSION GLP/1/EXENDIN 4 IgG Fc AUX FINS DU TRAITEMENT DU DIABETE
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2008054544A2 (fr) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Procédé d'administration à travers la barrière hématoencéphalique
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008116107A2 (fr) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Activateurs de glucokinase
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
AU2010238858A1 (en) * 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
WO2011107991A1 (fr) * 2010-03-02 2011-09-09 Protalix Ltd. Multimères de glucocérébrosidase et leurs utilisations
DK2665814T3 (en) 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2015009052A1 (fr) * 2013-07-16 2015-01-22 일동제약 주식회사 Protéine de fusion de fc hybride d'immunoglobuline et d'enzyme
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106456714A (zh) * 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6475486B1 (en) * 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1998022577A1 (fr) * 1996-11-15 1998-05-28 Maria Grazia Masucci Proteines de fusion a demi-vie allongee
DE69807679T2 (de) * 1997-04-17 2003-07-31 Amgen Inc., Thousand Oaks Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
AU772153B2 (en) * 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
IL151024A0 (en) * 2000-02-15 2003-02-12 Genzyme Corp Conjugates of a biopolymer and a therapeutic agent
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline

Also Published As

Publication number Publication date
MXPA03006294A (es) 2003-09-16
CA2435037A1 (fr) 2002-07-25
US20040043457A1 (en) 2004-03-04
HUP0401300A3 (en) 2005-06-28
EP1392826A2 (fr) 2004-03-03
WO2002057435A2 (fr) 2002-07-25
NO20033247L (no) 2003-07-17
ZA200306333B (en) 2004-11-17
JP2004525621A (ja) 2004-08-26
HUP0401300A2 (hu) 2004-09-28
CN1630720A (zh) 2005-06-22
PL362394A1 (en) 2004-11-02
BR0116803A (pt) 2004-02-17
KR20030067755A (ko) 2003-08-14
WO2002057435A3 (fr) 2003-12-24

Similar Documents

Publication Publication Date Title
NO20033247D0 (no) Bifunksjonelle fusjonsproteiner med glukocerebrosidaseaktivitet
CY2014040I1 (el) Πρωτεϊνη συντηξης αλβουμινης
IL166751A0 (en) Modified transferin-antibody fusion proteins
DE60234432D1 (de) Umbales zwischenwirbelfusionsverfahren
DK2236152T3 (da) Albuminfusionsproteiner
FR2856445B1 (fr) Joint homocinetique tripode
IT1313881B1 (it) Giunto omocinetico
DE60004380D1 (de) Gelenkanordnung
DE60235603D1 (de) Fusionsprotein mit gesteigerter in vivo Erythropoietin-Aktivität
ATE515269T1 (de) Gag-bindende proteine
ID29577A (id) Protein pestisida
DK1056448T3 (da) Farmaceutiske kombinationer med tramadol
DE60003212D1 (de) Druckkopf
GB9913437D0 (en) Fusion proteins
NO20021275D0 (no) Transgent produserte fusjonsproteiner
DK1058069T3 (da) Absorber
DE10082339T1 (de) Antriebsgelenk
DE60007214D1 (de) Mehrteiliges Federgelenk
GB0200689D0 (en) Fusion proteins
ITMI20021241A1 (it) Giunto cardanico doppio centrato
DE10082298D2 (de) Chimäre Proteine
DE10084565T1 (de) Verbindungsorgan
NO20021244L (no) Subenhet-optimaliserte fusjonsproteiner
EP1209231A4 (fr) Proteine meg-1
DE60237589D1 (de) Fusionsproteine